<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FC3BA2C-2950-4D6C-A7CA-1F9F132865CE"><gtr:id>1FC3BA2C-2950-4D6C-A7CA-1F9F132865CE</gtr:id><gtr:name>London Biotechnology Network</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FC3BA2C-2950-4D6C-A7CA-1F9F132865CE"><gtr:id>1FC3BA2C-2950-4D6C-A7CA-1F9F132865CE</gtr:id><gtr:name>London Biotechnology Network</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/148589EF-A798-492F-B74D-A321FF038C12"><gtr:id>148589EF-A798-492F-B74D-A321FF038C12</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:surname>Waldman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5B1BC4D3-DB25-42AE-A1E3-F5FE202F977D"><gtr:id>5B1BC4D3-DB25-42AE-A1E3-F5FE202F977D</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:surname>Giovannoni</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2BC340ED-3EC7-4AEF-B5AF-ED975B2FF849"><gtr:id>2BC340ED-3EC7-4AEF-B5AF-ED975B2FF849</gtr:id><gtr:firstName>Omar</gtr:firstName><gtr:surname>Malik</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5B39CCF7-170B-4734-8AA4-A3BB115E9BA2"><gtr:id>5B39CCF7-170B-4734-8AA4-A3BB115E9BA2</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>St.</gtr:otherNames><gtr:surname>Nicholas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A5B5D46-3F7B-4F71-A7B2-6EAC51B37517"><gtr:id>3A5B5D46-3F7B-4F71-A7B2-6EAC51B37517</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Chataway</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CD462D80-9C9F-4E67-A4AF-2AF2DCEA83BE"><gtr:id>CD462D80-9C9F-4E67-A4AF-2AF2DCEA83BE</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Reynolds</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FA38795B-FFB9-4EFB-A47B-BEC70ABDDD0F"><gtr:id>FA38795B-FFB9-4EFB-A47B-BEC70ABDDD0F</gtr:id><gtr:firstName>Paolo</gtr:firstName><gtr:otherNames>Paolo</gtr:otherNames><gtr:surname>Muraro</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D12B33A-B0C9-4A01-BF33-C945D0BCBC18"><gtr:id>2D12B33A-B0C9-4A01-BF33-C945D0BCBC18</gtr:id><gtr:firstName>Klaus</gtr:firstName><gtr:surname>Schmierer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800679"><gtr:id>1AE19330-F365-4E8B-8DB3-4F33F3996F31</gtr:id><gtr:title>Rapidly evolving multiple sclerosis: opening the window of therapeutic opportunity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800679</gtr:grantReference><gtr:abstractText>Multiple Sclerosis (MS) is a demyelinating disease of the nervous system that represents the most common cause of disability in young adults. It is a long-term disease with a significant medical, economic and social impact, largely due to the accumulation of disability. Results of studies and clinical practice show that patients affected by rapidly evolving form of MS may not benefit from the available immunomodulatory drugs and are at high risk to become disabled. We want to establish a group (?cohort?) of patients with very active forms of MS that has not been controlled by the standard treatments. With ethical approval and the consent of each patient who wishes to enter this cohor, we plan to study in great detail the characteristics of disease in each subject by clinical tests, brain scans, blood and spinal fluid tests for indices of inflammation and by mapping some variations of genes that are associated with MS. With this information we will be able to identify within the group the most suitable patients who could benefit from new therapies being studied. The patients participating in the cohort will have the option to participate in the clinical trial most suitable to them. By accelerating the access of candidate patients, the clinical trials will be run more efficiently, speeding up the development of effective cures for MS.</gtr:abstractText><gtr:technicalSummary>Multiple sclerosis (MS) is a heterogeneous inflammatory and degenerative disease of the central nervous system that presents with a variable clinical course and a broad spectrum of severity. This heterogeneity is likely to reflect at least in part the involvement of different components to the pathogenesis of the disease, as suggested by studies of MS lesion pathology. Clinical and pathological heterogeneity in patient populations represents a difficulty in the evaluation of responses to MS therapies. However, progress in the characterisation of the components of MS pathogenesis and the increasing availability of biological agents targeting specific cell populations or functions now offer great opportunity to develop more individualised and effective therapies.

By establishing a research cohort of patients with rapidly evolving MS in a relatively early stage of disease we intend to maximise the opportunity to develop effective therapies. Our group has expertise in state-of-the-art methodologies for clinical, immunological, genetic and genome-wide transcriptional characterisation of MS phenotypes. Systematic collection of phenotypic data within the research cohort will allow delineating homogenous subgroups of patients who are appropriate candidates to clinical trials of new therapeutics. By developing search algorithms for existing or newly designed academic- or industry-driven clinical trials we will be able to rapidly and objectively identify patient subgroups with specific disease characteristics. 

The products that our research cohort programme can deliver are (i) providing to patients with rapidly evolving MS the option to participate in trials of novel therapeutics exploiting the appropriate window of therapeutic opportunity, and (ii) to drive development of novel pharmacological or cell therapies through an innovative model to efficiently recruit specific patient populations.</gtr:technicalSummary><gtr:fund><gtr:end>2014-11-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>494742</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Natural history of MS</gtr:description><gtr:id>560C2B48-ED5B-4104-8F84-21E4B3CABBD8</gtr:id><gtr:impact>Two publications and a funded project grant.</gtr:impact><gtr:outcomeId>Z8NqsYENNBE-1</gtr:outcomeId><gtr:partnerContribution>Study of natural history of MS</gtr:partnerContribution><gtr:piContribution>To provide access, analytical tools and expertise to analysis of clinical databases of MS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imanova</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with GSK and Imanova</gtr:description><gtr:id>097CB6C8-FE3A-4067-9DC6-7CB41188EFE3</gtr:id><gtr:impact>Workshop on stratified medicine held 5 October 2012.</gtr:impact><gtr:outcomeId>cPCw1sREC97-2</gtr:outcomeId><gtr:partnerContribution>Developing methods and tools for stratified medicine, novel imaging methods.</gtr:partnerContribution><gtr:piContribution>Providing anonymised, aggregate data access to a well-defined patient cohort with advanced imaging analysis and identify unmet healthcare needs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London Biotechnology Network</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Participation in London Biotechnology Network</gtr:description><gtr:id>C83A0ADA-B197-4700-BD76-266168BA143A</gtr:id><gtr:impact>Publication of the Bioguide London (Ageing and CNS/Neurodegenerative Disorders) directory published by the LBN and available online at www.londonbiotechnology.co.uk.</gtr:impact><gtr:outcomeId>D52D4D496CE-1</gtr:outcomeId><gtr:partnerContribution>The partnership has allowed us to share information about the project with the Network, which has been followed by increased contacts with industry and academic colleagues that have the potential to evolve into collaboration and partnership.</gtr:partnerContribution><gtr:piContribution>We have participated and given a presentation in the annual event at the BioGuide London Symposium &amp;quot;Ageing &amp;amp; CNS/Neurodegenerative Disorders&amp;quot; , a business network of over 800 organisations/2000 members from the biopharmaceutical sector, academia and other partners. The event was held at the UCL Institute of Neurology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration with GSK and Imanova</gtr:description><gtr:id>C890BBB3-5385-4911-9C1C-F4D2F37774B4</gtr:id><gtr:impact>Workshop on stratified medicine held 5 October 2012.</gtr:impact><gtr:outcomeId>cPCw1sREC97-1</gtr:outcomeId><gtr:partnerContribution>Developing methods and tools for stratified medicine, novel imaging methods.</gtr:partnerContribution><gtr:piContribution>Providing anonymised, aggregate data access to a well-defined patient cohort with advanced imaging analysis and identify unmet healthcare needs.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Medicine</gtr:department><gtr:description>Cambridge</gtr:description><gtr:id>6F4B2CAC-2398-4559-86CC-544A23D2D9D2</gtr:id><gtr:impact>Work in progress.</gtr:impact><gtr:outcomeId>A8PfRGR33Ws-1</gtr:outcomeId><gtr:partnerContribution>Provide HLA typing for immunogenetics studies and genotype/phenotype association studies.</gtr:partnerContribution><gtr:piContribution>Provided biosamples from consented patients with active multiple sclerosis wishing to participate in genetics studies of the International MS Genetics Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MS Study day 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C53DDA40-2A08-4B60-894F-06A89A3497C1</gtr:id><gtr:impact>Describe current clinical trials and research

Patient enquiries about trials</gtr:impact><gtr:outcomeId>aSrr7decuRo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS study day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BB48EDF0-041F-436E-89A2-A00B65AF6915</gtr:id><gtr:impact>&amp;gt;200 patients with MS and their families attended a presentation at this MS study day. Excellent feedback was returned.

Increased recruitment in the research cohort</gtr:impact><gtr:outcomeId>qcc1QXQQfys</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Study day on MS Treatments: the next steps</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>37CA106C-BF7F-4457-88C9-2FAC93B9E824</gtr:id><gtr:impact>An information up-date study day for people with MS, their relatives, and clinicians was held at Ealing Town Hall on March 24th 2010. The meeting was attended by &amp;gt;100 patients and by representatives of the MS Society and the MS Trust. Updates on treatments and clinical trials including the PRCI Rapidly evolving MS were presented and discussed with the patients.


Majority of Participants' evaluation form return rated very high or high the quality of information presented in the MS study day. An increased interest in participating in clinical trials was noted in patients attending the MS service at Charing Cross Hospital.</gtr:impact><gtr:outcomeId>HTZVDXGq14E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Matters magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F9C9C3F-3AF0-4A43-B98D-06CA02CB6145</gtr:id><gtr:impact>Article about the MRC funded project was published in the MS matters magazine, a quarterly magazine printed and distributed nationally and also available online for people with MS and healthcare professionals.

Increased number of self-referrals.</gtr:impact><gtr:outcomeId>EAxE3PyPAqG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Barts and the London NHS Trust multiple sclerosis study day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3A6CE44D-9751-45FA-AE85-B6570A56FDE1</gtr:id><gtr:impact>Over 200 patients and their families together with health professional attended the meeting. We had both a talk given by the PI introducing the patient research cohort initiative and a poster presented by the Research Nurse and the PI that was well attended. We also distributed printed referral information.

Disseminating the PRCI resulted in some patient self-referrals to the Cohort as well as increased awareness by clinicians at Barts and the London NHS Trust about our initiative.</gtr:impact><gtr:outcomeId>dCq8Fyi5d7M</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meet the scientist annual day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>326482B9-AC3D-49BA-97BB-95BA209B3774</gtr:id><gtr:impact>The event consisted of an open day in our labs at the Burlington Danes Building, Hammersmith Campus, Imperial College for people with Parkinson's, Alzheimer's and MS and the aims are both to help them learn about research on the disorder that affects them and to provide an opportunity for basic (non-clinical) researchers to connect with and be inspired in their research by real people with the disease they are studying.

Questionnaire results revealed that the majority found day enjoyable, informative and accessible to participants.</gtr:impact><gtr:outcomeId>g2PgGMbeynd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60298</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Italian Multiple Sclerosis Society (AISM)</gtr:fundingOrg><gtr:fundingRef>2010/R/24</gtr:fundingRef><gtr:id>8DD7EE9A-8F55-4DD0-8CB2-FC836FE7EAA7</gtr:id><gtr:outcomeId>D2CHiTEf9cZ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38732</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Italian Multiple Sclerosis Society (AISM)</gtr:fundingOrg><gtr:id>C1FC57B0-19EB-4BDE-8A4F-9501F434A3B2</gtr:id><gtr:outcomeId>iLLgeo82XwD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>235464</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>938/10</gtr:fundingRef><gtr:id>047313C4-F739-44D9-A260-9303EA799BEB</gtr:id><gtr:outcomeId>U3sssJJS89w0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2055691</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>15AE5298-DD36-43C0-82D9-9D0F85842EC7</gtr:id><gtr:outcomeId>dHiJim6SpW10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106995</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N026934/1</gtr:fundingRef><gtr:id>855557AE-CE2B-438D-A676-A7ADA432A1B0</gtr:id><gtr:outcomeId>58ca917a59ed14.80132435</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative Project Grant</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>944/10</gtr:fundingRef><gtr:id>061156F6-221E-4E6C-A564-49DCF0268261</gtr:id><gtr:outcomeId>on78B74eUvQ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112768</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Junior Fellowship</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>975/12</gtr:fundingRef><gtr:id>8DDA6BE6-2205-4137-8892-AB2B087FF998</gtr:id><gtr:outcomeId>54638af71a9f14.72943597</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Italian Multiple Sclerosis Society (AISM)</gtr:fundingOrg><gtr:fundingRef>2015/R/16</gtr:fundingRef><gtr:id>D259BB9C-DC94-43E2-8219-55D60DBEBDA4</gtr:id><gtr:outcomeId>56e024ce6c5c35.07484109</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53333</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AISM Research Grant</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Italian Multiple Sclerosis Society (AISM)</gtr:fundingOrg><gtr:id>1DE0783D-AAA3-4BFC-9807-0DC1A4FCB106</gtr:id><gtr:outcomeId>A040A90DBBF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40419</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:fundingRef>WMCN P36769</gtr:fundingRef><gtr:id>A2CFA7CF-3979-4DC3-9A5A-3FEAABB813E9</gtr:id><gtr:outcomeId>hDgYDWyrbYD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>63575</gtr:amountPounds><gtr:country>Italy, Italian Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Fellowship</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Italian Multiple Sclerosis Society (AISM)</gtr:fundingOrg><gtr:fundingRef>Prot. N. 23/13/F1</gtr:fundingRef><gtr:id>10FE4684-B5BF-4C07-BE48-AC76C2D97D37</gtr:id><gtr:outcomeId>54638a4c855139.87626064</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant from Multiple Sclerosis Trial Collaboration (recognized charity)</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Trials Collaboration</gtr:fundingOrg><gtr:id>6118AD34-1D47-42C0-9F16-32D1B5EE6BD8</gtr:id><gtr:outcomeId>71DD8CE20FD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>239831</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C9065339-43E5-4A61-9AA5-C054B1210C6B</gtr:id><gtr:outcomeId>FTmwKWvbkhE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Running the first randomised controlled trial of mesenchymal stem cell therapy in active multiple sclerosis that received MHRA clinical trial authorisation (CTA) as advanced therapy medicinal product (ATMP).</gtr:description><gtr:id>453835C0-4D69-44CC-ADA6-462752D8B072</gtr:id><gtr:impact>Established a regulatory approval precedent and feasibility of the intervention.</gtr:impact><gtr:outcomeId>qzWT219yABP</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical Trial of MSC in MS</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01606215</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A database to enter multiple sclerosis patients data and to organize the research cohort biosample inventory were developed.</gtr:description><gtr:id>1D3EF75B-E79F-471C-AB7A-5D57F234031A</gtr:id><gtr:impact>The database and biosample software will support additional studies within the group and outside collaborations.</gtr:impact><gtr:outcomeId>AF5E63456C5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Patient research cohort and biosample database.</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have indexed and analysed all clinical trials in the UK for which public information exists and that would be in principle applicable to the PRCI population. A database has been created, is being periodically updated and it utilised to match PRCI subjects to clinical trials.</gtr:description><gtr:id>D7EAEC69-2C4F-4E29-99A3-D26F5F6DC449</gtr:id><gtr:impact>Essential to run the PRCI cohort, this database might benefit additional users.</gtr:impact><gtr:outcomeId>TzXrZ7un2Zh</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Clinical trials database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>535FE8AF-1BA7-4E67-B42D-AF0E2991AE2E</gtr:id><gtr:title>Age and disability accumulation in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d18e551fc34b44b0cdc01fdfbc6844"><gtr:id>92d18e551fc34b44b0cdc01fdfbc6844</gtr:id><gtr:otherNames>Scalfari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>oyLsfsbsf21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71143407-682B-42AC-9366-7B114F900D09</gtr:id><gtr:title>Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d03890848f930352bf577a78713adc2f"><gtr:id>d03890848f930352bf577a78713adc2f</gtr:id><gtr:otherNames>Mattoscio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5675e0b9ad882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7BF0D3D-327A-4F46-93B7-0600DACC3372</gtr:id><gtr:title>Resetting autoimmunity in the nervous system: The role of hematopoietic stem cell transplantation.</gtr:title><gtr:parentPublicationTitle>Current opinion in investigational drugs (London, England : 2000)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67b59c22e759cafc963c3b274b2d1e03"><gtr:id>67b59c22e759cafc963c3b274b2d1e03</gtr:id><gtr:otherNames>Muraro PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-4472</gtr:issn><gtr:outcomeId>pm_540e15ee15ea05508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9737B7A-DD9E-4807-B19A-4DFA74EBA88D</gtr:id><gtr:title>A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimaging : official journal of the American Society of Neuroimaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a9a35226f2eedd3de0e04419da1bfc3"><gtr:id>7a9a35226f2eedd3de0e04419da1bfc3</gtr:id><gtr:otherNames>Lema A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1051-2284</gtr:issn><gtr:outcomeId>585d3a21a715b5.86460347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C4ED2B-6B2B-45D9-9714-549DA287D91D</gtr:id><gtr:title>In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>54638387bd3158.67230106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31FC33CA-B072-41CC-BEBE-A56ADC5D125B</gtr:id><gtr:title>Early relapses, onset of progression, and late outcome in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d18e551fc34b44b0cdc01fdfbc6844"><gtr:id>92d18e551fc34b44b0cdc01fdfbc6844</gtr:id><gtr:otherNames>Scalfari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5463845b199e99.71344374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC9843AC-04FB-48F3-A588-E3DB50985412</gtr:id><gtr:title>A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/507652bad79c26b7779acad3ddf7e155"><gtr:id>507652bad79c26b7779acad3ddf7e155</gtr:id><gtr:otherNames>Galea I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>doi_15026__ene_12016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03E39E8-5CD3-4C8A-B9E7-E6AE0C1C8A3E</gtr:id><gtr:title>Onset of secondary progressive phase and long-term evolution of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d18e551fc34b44b0cdc01fdfbc6844"><gtr:id>92d18e551fc34b44b0cdc01fdfbc6844</gtr:id><gtr:otherNames>Scalfari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>doi_15026_012_304333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>346853F0-BCE5-450C-9D98-CF6DA8DB0078</gtr:id><gtr:title>A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea955d345c69f7e848f4a54ba991e50b"><gtr:id>ea955d345c69f7e848f4a54ba991e50b</gtr:id><gtr:otherNames>Saccardi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>pm_15026_26_22383228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85ACFCD8-3316-4252-B142-D437561E6F6B</gtr:id><gtr:title>The relationship of age with the clinical phenotype in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d18e551fc34b44b0cdc01fdfbc6844"><gtr:id>92d18e551fc34b44b0cdc01fdfbc6844</gtr:id><gtr:otherNames>Scalfari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>585d649eaf9de6.27602707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>857A5114-9BDA-441D-A1F2-A7120AE11B5B</gtr:id><gtr:title>Drugs in development for relapsing multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf70ed2f01d90aa13c84964e3c90e2bb"><gtr:id>cf70ed2f01d90aa13c84964e3c90e2bb</gtr:id><gtr:otherNames>Ali R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>pm_15026_26_23609782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1FCB9B-D65D-4AD5-94D9-0E0186AAED67</gtr:id><gtr:title>Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time?</gtr:title><gtr:parentPublicationTitle>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54b6407fd903bc465375e5b35ea812fe"><gtr:id>54b6407fd903bc465375e5b35ea812fe</gtr:id><gtr:otherNames>Atkins HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1083-8791</gtr:issn><gtr:outcomeId>pm_15026_26_22226104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1AE2E0B-8885-40E7-9326-9293B98EB223</gtr:id><gtr:title>Positron emission tomography imaging in multiple sclerosis-current status and future applications.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db97ea751e9e6c6ac87cd417ad0726b5"><gtr:id>db97ea751e9e6c6ac87cd417ad0726b5</gtr:id><gtr:otherNames>Kiferle L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>oCugE1yBBk9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>489B3A71-F5BA-4AC9-AC95-7437E2B207DF</gtr:id><gtr:title>Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac374eaf02bb39818ac1a7a6da55fb05"><gtr:id>ac374eaf02bb39818ac1a7a6da55fb05</gtr:id><gtr:otherNames>Colasanti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>56e021de727603.05933187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84461A51-6A6F-400F-B3AA-1E035F62DC53</gtr:id><gtr:title>The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92d18e551fc34b44b0cdc01fdfbc6844"><gtr:id>92d18e551fc34b44b0cdc01fdfbc6844</gtr:id><gtr:otherNames>Scalfari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_15026_26_20534650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79BC31D-D38F-46E0-9E44-DB29B0167557</gtr:id><gtr:title>Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/facbb5c233e71f33d3b5739a16a616de"><gtr:id>facbb5c233e71f33d3b5739a16a616de</gtr:id><gtr:otherNames>Newbould RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>546382ace9e9f7.46596129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E69578A-8767-4FB7-A8AE-23299EB6DDA1</gtr:id><gtr:title>Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e9e16e509b244bdf44316b6874926f4"><gtr:id>9e9e16e509b244bdf44316b6874926f4</gtr:id><gtr:otherNames>Bishop CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>58ca8fb91c87a9.16618025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ED4CD06-6802-4B8C-9C1D-850A8639E9B2</gtr:id><gtr:title>Escalating immunotherapies for highly active multiple sclerosis: Reviewing the evidence</gtr:title><gtr:parentPublicationTitle>Current Medical Literature - Multiple Sclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3e9ee66aa2cca55ed4db7f2470249dd"><gtr:id>b3e9ee66aa2cca55ed4db7f2470249dd</gtr:id><gtr:otherNames>Scalfari A, Nicholas R, Malik O, and Muraro PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>ERJ49Cq5z9W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC1A608D-E688-4E32-A181-FC754E72D037</gtr:id><gtr:title>Development of oral immunomodulatory agents in the management of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Drug design, development and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5163af1563a463de4560f1b58baad41"><gtr:id>c5163af1563a463de4560f1b58baad41</gtr:id><gtr:otherNames>Nicholas R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1177-8881</gtr:issn><gtr:outcomeId>29492E4A_329492E4A_3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800679</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>